# Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms

> **NCT03006029** · PHASE1 · COMPLETED · sponsor: **Theramab LLC** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** TAB08

## Key facts

- **NCT ID:** NCT03006029
- **Lead sponsor:** Theramab LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-08
- **Primary completion:** 2019-05-14
- **Final completion:** 2019-08-13
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006029, "Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03006029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*